RecruitingPhase 2NCT07333716
Desloratadine in Patients With Ulcerative Colitis
Efficacy and Safety of Desloratadine as Adjuvant Therapy in Patients With Ulcerative Colitis
Sponsor
Tanta University
Enrollment
44 participants
Start Date
Jan 26, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to investigate safety and therapeutic efficacy of antihistamine (desloratadine) on inflammation and disease activity when administered as adjuvant therapies with the traditional therapy 5-aminosalisylic acid (mesalamine) in patients with mild to moderate ulcerative colitis.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria4
- Both male and female sex.
- patients with age ranged from 18 to 65.
- patients with active mild and moderate ulcerative colitis according to American College of Gastroenterology (ACG) Clinical Guideline.
- Patients treated with 5-aminosalisylic acid (mesalamine).
Exclusion Criteria9
- Patients with severe UC
- Significant liver or kidney function abnormalities
- Pregnant or lactating females
- Treatment with systemic or rectal steroids
- Treatment with immunosuppressant or biological therapies
- Known allergy to desloratadine or any ingredient in the formulation
- Patients with other inflammatory diseases
- Patients with history of colon cancer
- Patients with complete or partial colectomy
Interventions
DRUGDesloratadine
mesalamine 1000 mg three times daily plus desloratadine 5 mg once daily for 3 months.
DRUGmesalamine
mesalamine 1000 mg three times daily for 3 months
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07333716
Related Trials
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
NCT060713121 location
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
NCT0609512849 locations
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
NCT0658132891 locations
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT0381634552 locations
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
NCT072375165 locations